Long acting GLP-1 receptor agonist (injectable)
Liraglutide 2.4 mg injection once daily
LIRA_SC_2p4MG_QD
Related
- All doses pooled: Liraglutide injection
- Liraglutide 1.8 mg subcutaneous once daily
- Liraglutide flexible dose injection once daily
- Liraglutide 3.0 mg subcutaneous once daily
- Liraglutide maximum tolerated dose injection once daily
- Liraglutide 0.9 mg injection once daily
- Liraglutide flexible dose injection once daily
- Liraglutide 1.2 mg subcutaneous once daily
- Liraglutide maximum tolerated dose injection once daily
- Liraglutide 0.6 mg subcutaneous once daily
- Liraglutide subcutaneous once daily, flexible dose: 1.2 or 1.8 mg by tolerability
- Liraglutide maximum tolerated dose injection once daily
- Liraglutide maximum tolerated dose injection once daily
- Liraglutide 0.6 mg injection
- Liraglutide 1.2 mg injection
- Liraglutide 1.25UG/KG injection once daily
- Liraglutide 5.0UG/KG injection once daily
- Liraglutide 7.5UG/KG injection once daily
- Liraglutide 10UG/KG injection once daily
- Liraglutide 12.5UG/KG injection once daily
- Liraglutide 0.3 mg injection once daily
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Overweight or obesity without diabetes (adults) | Systolic blood pressure change | weeks 20 to 40 (target week 26) | Placebo | MD -6.45 (-15.65 to 2.63) | 0.71 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.05 (0.27 to 3.48) | 0.53 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 3.30 (2.28 to 4.85) | 0.55 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 4.88 (2.60 to 9.15) | 0.45 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.32 (0.56 to 2.91) | 0.66 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 2.56 (1.14 to 5.71) | 0.40 |
Trials
- NCT00422058Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes: A 20-week Randomised, Double-blind, Placebo-controlled, Six Armed Parallel Group, Multi-centre, Multinational Trial With an Open Label Orlistat Comparator Arm and With an 84-week Extension Period2007 · 564 randomized · 52 weeks
- S0030672007 · 564 randomized · 52 weeks